Peter Heerma
CIK 1789617 · CHIEF COMMERCIAL OFFICER · last filed 2026-05-06
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$9.24M
Companies
2
Total Filings
40
Lifetime Open-Market Net
-$2.04M
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| TVTX | CHIEF COMMERCIAL OFFICER | 140,684 | $65.71 | $9.24M | -$1.96M | 26 | 2026-05-06 |
| Travere Therapeutics, Inc. (RTRX) Delisted | Chief Commercial Officer | 44,517 | — | — | -$83.7K | 3 | 2020-10-05 |
Recent Filings · Page 4 of 4
40 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2022-01-26 | TVTX | Sell (S) | −1,875 | -$46.8K | EDGAR |
| 2021-10-05 | TVTX | Sell (S) | −3,058 | -$75.7K | EDGAR |
| 2021-08-17 | TVTX | Mixed | +3,093 | -$24.1K | EDGAR |
| 2021-02-09 | TVTX | Sell (S) | −2,250 | -$70.9K | EDGAR |
| 2021-02-05 | TVTX | Grant (A) | +4,500 | $0 | EDGAR |
| 2021-02-03 | TVTX | Sell (S) | −1,126 | -$33.6K | EDGAR |
| 2021-01-25 | TVTX | Grant (A) | +15,000 | $0 | EDGAR |
| 2020-10-05 | Travere Therapeutics, Inc. (RTRX) Delisted | Sell (S) | −4,376 | -$83.7K | EDGAR |
| 2020-01-31 | Travere Therapeutics, Inc. (RTRX) Delisted | Grant (A) | +9,000 | $0 | EDGAR |
| 2019-10-02 | Travere Therapeutics, Inc. (RTRX) Delisted | Grant (A) | +35,000 | $0 | EDGAR |
Showing 31–40 of 40
Prev
Page 4 of 4
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.